Systemic therapies: optimising the sequences of chemotherapies, targeted therapies and immunotherapies

Thierry Berghmans (Bruxelles, Belgium)

Source: International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy

Session: PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy
Session type: Postgraduate Course
Number: 87

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Thierry Berghmans (Bruxelles, Belgium). Systemic therapies: optimising the sequences of chemotherapies, targeted therapies and immunotherapies. International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Concomitant radiotherapy and targeted therapies Source: International Congress 2019 – New perspectives in thoracic surgical oncology Year: 2019
Novel targets and emerging therapies in MPM Source: ERS Skills course: Multi-disciplinary care in thoracic oncology Year: 2019
Combination therapy in the era of immunotherapy Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019
Targeting targeted therapies: more choices and the best sequences Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer Year: 2018
Potential of regulatory T-cell-based therapies in the management of severe COVID-19 Source: Eur Respir J, 56 (3) 2002182; 10.1183/13993003.02182-2020 Year: 2020
Achievements in targeted therapies Source: Eur Respir Monogr 2015; 68: 215-233 Year: 2015
Better diagnostics for targeted antibiotic therapy Source: Virtual Congress 2020 – Antibiotic resistance: the way forward Year: 2020
From anti-PD1/L1 inhibitors to new immunotherapies Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019
Optimizing the target therapy development Source: ERS Research Seminar Year: 2015
Innovative systemic lung cancer therapies Source: International Congress 2018 – PG11 Modern approaches in lung cancer diagnostics and therapy Year: 2018
Malignant mesothelioma: new treatment advances, including targeted therapies Source: Virtual Congress 2021 – Diagnostic and therapeutic advances in mesothelioma care Year: 2021
Alternative immunosuppressive strategies Source: ERS Course 2016 Year: 2016